Mark Pruzanski - 30 Jun 2021 Form 4 Insider Report for INTERCEPT PHARMACEUTICALS, INC.

Role
Director
Signature
/s/ Mary J. Grendell, as attorney-in-fact
Issuer symbol
N/A
Transactions as of
30 Jun 2021
Net transactions value
+$46,330
Form type
4
Filing time
01 Jul 2021, 19:01:27 UTC
Previous filing
02 Jun 2021
Next filing
02 Aug 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ICPT Common Stock Award $122,536 +6,136 +1% $19.97 611,106 30 Jun 2021 Direct F1
transaction ICPT Common Stock Tax liability $76,206 -3,816 -0.62% $19.97 607,290 30 Jun 2021 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock delivered in respect of performance stock unit awards previously granted to the reporting person; such delivery being made pursuant to the Retirement and Consulting Agreement by and between the Issuer and the reporting person, dated December 9, 2020.
F2 Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock unit and performance stock unit awards previously granted to the reporting person.